• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

miRNAs 的综合分析表明它们广泛影响高级别浆液性卵巢癌中的基因表达。

Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma.

机构信息

Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, United States of America.

出版信息

PLoS One. 2012;7(3):e34546. doi: 10.1371/journal.pone.0034546. Epub 2012 Mar 29.

DOI:10.1371/journal.pone.0034546
PMID:22479643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3315571/
Abstract

BACKGROUND

The Cancer Genome Atlas (TCGA) Network recently comprehensively catalogued the molecular aberrations in 487 high-grade serous ovarian cancers, with much remaining to be elucidated regarding the microRNAs (miRNAs). Here, using TCGA ovarian data, we surveyed the miRNAs, in the context of their predicted gene targets.

METHODS AND RESULTS

Integration of miRNA and gene patterns yielded evidence that proximal pairs of miRNAs are processed from polycistronic primary transcripts, and that intronic miRNAs and their host gene mRNAs derive from common transcripts. Patterns of miRNA expression revealed multiple tumor subtypes and a set of 34 miRNAs predictive of overall patient survival. In a global analysis, miRNA:mRNA pairs anti-correlated in expression across tumors showed a higher frequency of in silico predicted target sites in the mRNA 3'-untranslated region (with less frequency observed for coding sequence and 5'-untranslated regions). The miR-29 family and predicted target genes were among the most strongly anti-correlated miRNA:mRNA pairs; over-expression of miR-29a in vitro repressed several anti-correlated genes (including DNMT3A and DNMT3B) and substantially decreased ovarian cancer cell viability.

CONCLUSIONS

This study establishes miRNAs as having a widespread impact on gene expression programs in ovarian cancer, further strengthening our understanding of miRNA biology as it applies to human cancer. As with gene transcripts, miRNAs exhibit high diversity reflecting the genomic heterogeneity within a clinically homogeneous disease population. Putative miRNA:mRNA interactions, as identified using integrative analysis, can be validated. TCGA data are a valuable resource for the identification of novel tumor suppressive miRNAs in ovarian as well as other cancers.

摘要

背景

癌症基因组图谱(TCGA)网络最近全面编目了 487 例高级别浆液性卵巢癌中的分子异常,关于 microRNAs(miRNAs)仍有许多需要阐明。在这里,我们使用 TCGA 卵巢数据,在其预测基因靶标的背景下调查了 miRNAs。

方法和结果

miRNA 和基因模式的整合提供了证据表明,miRNAs 是从多顺反子初级转录物中加工而来的,并且内含子 miRNAs 和它们的宿主基因 mRNA 来自共同的转录物。miRNA 表达模式揭示了多个肿瘤亚型和一组 34 个可预测总患者生存的 miRNAs。在全局分析中,在肿瘤之间表达呈反相关的 miRNA:mRNA 对在 mRNA 3'-非翻译区(在编码序列和 5'-非翻译区观察到的频率较低)中具有更高频率的计算机预测靶位点。miR-29 家族和预测的靶基因是表达最强烈反相关的 miRNA:mRNA 对之一;miR-29a 在体外过表达抑制了几个反相关基因(包括 DNMT3A 和 DNMT3B),并显著降低了卵巢癌细胞活力。

结论

本研究确立了 miRNAs 对卵巢癌基因表达程序具有广泛的影响,进一步加强了我们对 miRNA 生物学的理解,因为它适用于人类癌症。与基因转录物一样,miRNAs 表现出高度的多样性,反映了临床同质疾病人群中基因组的异质性。使用综合分析鉴定的推定 miRNA:mRNA 相互作用可以得到验证。TCGA 数据是鉴定卵巢癌以及其他癌症中新型肿瘤抑制性 miRNAs 的宝贵资源。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/83efe83188c9/pone.0034546.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/25bdf79964e3/pone.0034546.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/c0a9f6ccad50/pone.0034546.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/67e5b71c812a/pone.0034546.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/d80d0b98fee4/pone.0034546.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/6369bbe9de6c/pone.0034546.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/83efe83188c9/pone.0034546.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/25bdf79964e3/pone.0034546.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/c0a9f6ccad50/pone.0034546.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/67e5b71c812a/pone.0034546.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/d80d0b98fee4/pone.0034546.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/6369bbe9de6c/pone.0034546.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f05e/3315571/83efe83188c9/pone.0034546.g006.jpg

相似文献

1
Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma.miRNAs 的综合分析表明它们广泛影响高级别浆液性卵巢癌中的基因表达。
PLoS One. 2012;7(3):e34546. doi: 10.1371/journal.pone.0034546. Epub 2012 Mar 29.
2
miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma.miR-223 可能靶向非典型增生性浆液性肿瘤和高级别卵巢浆液性癌中的 SWI/SNF 复合物蛋白 SMARCD1。
Hum Pathol. 2017 Dec;70:98-104. doi: 10.1016/j.humpath.2017.10.008. Epub 2017 Oct 24.
3
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma.MiR-29a是转移性高级别浆液性癌中生存期较长的一种候选生物标志物。
Hum Pathol. 2016 Aug;54:74-81. doi: 10.1016/j.humpath.2016.03.010. Epub 2016 Apr 8.
4
Clinically relevant microRNAs in ovarian cancer.卵巢癌中具有临床相关性的微小RNA
Mol Cancer Res. 2015 Mar;13(3):393-401. doi: 10.1158/1541-7786.MCR-14-0424. Epub 2014 Oct 10.
5
[Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].[运用生物信息学分析鉴定与高级别浆液性卵巢癌复发相关的miRNA-mRNA调控网络中的关键分子]
Nan Fang Yi Ke Da Xue Xue Bao. 2023 Jan 20;43(1):8-16. doi: 10.12122/j.issn.1673-4254.2023.01.02.
6
The modularity and dynamicity of miRNA-mRNA interactions in high-grade serous ovarian carcinomas and the prognostic implication.高级别浆液性卵巢癌中miRNA-mRNA相互作用的模块化和动态性及其预后意义。
Comput Biol Chem. 2016 Aug;63:3-14. doi: 10.1016/j.compbiolchem.2016.02.005. Epub 2016 Feb 27.
7
MicroRNA signatures discriminate between uterine and ovarian serous carcinomas.微小 RNA 特征可区分子宫和卵巢浆液性癌。
Hum Pathol. 2018 Jun;76:133-140. doi: 10.1016/j.humpath.2018.02.019. Epub 2018 Mar 5.
8
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.用于高级别浆液性卵巢癌组织中微小RNA定量的稳定表达参考小非编码RNA的鉴定
J Cell Mol Med. 2016 Dec;20(12):2341-2348. doi: 10.1111/jcmm.12927. Epub 2016 Jul 15.
9
Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.mRNA 和 miRNA 谱的综合分析揭示了 miR-193 和 miR-210 作为不同乳腺癌分子亚型潜在调控生物标志物的作用。
BMC Cancer. 2021 Jan 18;21(1):76. doi: 10.1186/s12885-020-07731-2.
10
Serum-based six-miRNA signature as a potential marker for EC diagnosis: Comparison with TCGA miRNAseq dataset and identification of miRNA-mRNA target pairs by integrated analysis of TCGA miRNAseq and RNAseq datasets.基于血清的六种miRNA特征作为子宫内膜癌诊断的潜在标志物:与TCGA miRNA测序数据集的比较以及通过整合分析TCGA miRNA测序和RNA测序数据集鉴定miRNA-mRNA靶标对
Asia Pac J Clin Oncol. 2018 Oct;14(5):e289-e301. doi: 10.1111/ajco.12847. Epub 2018 Jan 30.

引用本文的文献

1
PROM1 and EFTUD2 Expression in High-Grade Clear Cell Renal Cell Carcinoma as a Molecular Marker for Survival Rate.PROM1和EFTUD2在高级别透明细胞肾细胞癌中的表达作为生存率的分子标志物
Int J Mol Sci. 2025 Jun 30;26(13):6296. doi: 10.3390/ijms26136296.
2
Immunohistological Examination of HEATR1 and SLC27A2 Expression in ccRCC Samples to Evaluate Their Potential as Prognostic Markers-A Preliminary Study.肾透明细胞癌样本中HEATR1和SLC27A2表达的免疫组织学检查以评估其作为预后标志物的潜力——一项初步研究
Cancers (Basel). 2025 Jul 3;17(13):2234. doi: 10.3390/cancers17132234.
3
Divergent trajectories to structural diversity impact patient survival in high grade serous ovarian cancer.

本文引用的文献

1
Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles.基于整合基因组特征预测浆液性卵巢肿瘤的复发时间和生存情况。
PLoS One. 2011;6(11):e24709. doi: 10.1371/journal.pone.0024709. Epub 2011 Nov 3.
2
Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation.miR-152 和 miR-148a 在卵巢癌中的表达改变与细胞增殖有关。
Oncol Rep. 2012 Feb;27(2):447-54. doi: 10.3892/or.2011.1482. Epub 2011 Oct 3.
3
Integrated genomic analyses of ovarian carcinoma.卵巢癌的综合基因组分析。
高级别浆液性卵巢癌中结构多样性的不同轨迹影响患者生存。
Nat Commun. 2025 Jul 1;16(1):5586. doi: 10.1038/s41467-025-60655-y.
4
LINC01270 Regulates the NF-κB-Mediated Pro-Inflammatory Response via the miR-326/LDOC1 Axis in THP-1 Cells.LINC01270通过miR-326/LDOC1轴在THP-1细胞中调节NF-κB介导的促炎反应。
Cells. 2024 Dec 8;13(23):2027. doi: 10.3390/cells13232027.
5
Prognostic Significance of Elevated UCHL1, SNRNP200, and PAK4 Expression in High-Grade Clear Cell Renal Cell Carcinoma: Insights from LC-MS/MS Analysis and Immunohistochemical Validation.UCHL1、SNRNP200和PAK4表达升高在高级别透明细胞肾细胞癌中的预后意义:来自液相色谱-串联质谱分析和免疫组化验证的见解
Cancers (Basel). 2024 Aug 14;16(16):2844. doi: 10.3390/cancers16162844.
6
The DNA methylome of pediatric brain tumors appears shaped by structural variation and predicts survival.小儿脑肿瘤的DNA甲基化组似乎受结构变异影响,并可预测生存率。
Nat Commun. 2024 Aug 8;15(1):6775. doi: 10.1038/s41467-024-51276-y.
7
An essential gene signature of breast cancer metastasis reveals targetable pathways.一种乳腺癌转移的关键基因特征揭示了可靶向的通路。
Breast Cancer Res. 2024 Jun 12;26(1):98. doi: 10.1186/s13058-024-01855-0.
8
An overview of challenges associated with exosomal miRNA isolation toward liquid biopsy-based ovarian cancer detection.基于液体活检的卵巢癌检测中外泌体微小RNA分离相关挑战概述。
Heliyon. 2024 Apr 25;10(9):e30328. doi: 10.1016/j.heliyon.2024.e30328. eCollection 2024 May 15.
9
Using cancer proteomics data to identify gene candidates for therapeutic targeting.利用癌症蛋白质组学数据鉴定治疗靶点的候选基因
Oncotarget. 2023 May 4;14:399-412. doi: 10.18632/oncotarget.28420.
10
Multiregional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos.多区域测序分析揭示了拉丁裔胃癌肿瘤中广泛的遗传异质性。
Cancer Res Commun. 2022 Nov 28;2(11):1487-1496. doi: 10.1158/2767-9764.CRC-22-0149. eCollection 2022 Nov.
Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166.
4
MicroRNA-26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11.microRNA-26b 在人乳腺癌中表达下调,并通过靶向 SLC7A11 诱导细胞凋亡。
FEBS Lett. 2011 May 6;585(9):1363-7. doi: 10.1016/j.febslet.2011.04.018. Epub 2011 Apr 14.
5
A microRNA survival signature (MiSS) for advanced ovarian cancer.一种用于晚期卵巢癌的 microRNA 生存签名(MiSS)。
Gynecol Oncol. 2011 Jun 1;121(3):444-50. doi: 10.1016/j.ygyno.2011.01.025. Epub 2011 Feb 26.
6
Mammalian microRNAs predominantly act to decrease target mRNA levels.哺乳动物的 microRNAs 主要作用是降低靶 mRNA 水平。
Nature. 2010 Aug 12;466(7308):835-40. doi: 10.1038/nature09267.
7
Signatures of RNA binding proteins globally coupled to effective microRNA target sites.与有效的 miRNA 靶位全局耦联的 RNA 结合蛋白特征。
Genome Res. 2010 Aug;20(8):1010-9. doi: 10.1101/gr.103259.109. Epub 2010 May 27.
8
Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.分子谱分析揭示了 microRNA-31 在抑制浆液性卵巢癌和其他癌症增殖方面与 p53 相关的作用。
Cancer Res. 2010 Mar 1;70(5):1906-15. doi: 10.1158/0008-5472.CAN-09-3875. Epub 2010 Feb 23.
9
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.整合基因组分析确定了具有 PDGFRA、IDH1、EGFR 和 NF1 异常的胶质母细胞瘤的临床相关亚型。
Cancer Cell. 2010 Jan 19;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020.
10
MicroRNAs in cancer: small molecules with a huge impact.癌症中的微小RNA:具有巨大影响的小分子。
J Clin Oncol. 2009 Dec 1;27(34):5848-56. doi: 10.1200/JCO.2009.24.0317. Epub 2009 Nov 2.